tirzepatide vision problems New Research Confirms Weight-Loss Drug Link With Sudden Loss : ScienceAlert Zepbound Blindness Lawsuit [2026 Update]

A combination of genetic, vascular, and environmental factors may contribute to its development

PMCID: PMC4124142

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a landmark Phase 3 cardiovascular outcomes trial enrolling 17,604 adults with preexisting cardiovascular disease and obesity or overweight, but WITHOUT diabetes

How quickly does Tirzepatide ODT start working

Glucose control and vascular complications in veterans with type 2 diabetes

Key findings from the trial: Around 11% average weight loss at 42 weeks About 2% weight loss in the placebo group Zero vomiting reported at the most effective dose Tolerability similar to placebo Why is this important